Caris Life Sciences (CAI) Cash from Financing Activities (2024 - 2026)

Caris Life Sciences' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $824000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 35.88% year-over-year to $824000.0 in Q1 2026; TTM through Mar 2026 was $664.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $665.0 million, up 232.01% from the prior year.
• Cash from Financing Activities eased to $824000.0 in Q1 2026 per CAI's latest filing, from $3.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $681.4 million in Q2 2025 and bottomed at -$21.1 million in Q3 2025.
• The 3-year median for Cash from Financing Activities is $824000.0 (2026), against an average of $95.2 million.
• Biggest YoY gain for Cash from Financing Activities was 1403.98% in 2025; the steepest drop was 24349.43% in 2025.
• Year by year, Cash from Financing Activities stood at $226000.0 in 2024, then surged by 1403.98% to $3.4 million in 2025, then slumped by 75.76% to $824000.0 in 2026.
• Per Business Quant, the three latest CAI Cash from Financing Activities figures stand at $824000.0 (Q1 2026), $3.4 million (Q4 2025), and -$21.1 million (Q3 2025).